Spondyloarthritis & psoriatic arthritis
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)
Authors' conclusion
The incidence of serious infection was low for PsA patients who were new users of targeted therapies in real-world settings. Relative to adalimumab new users, this risk was lower among new users of etanercept and ustekinumab and unmodified for the other molecules.
Study context
- Population
- All adults with psoriatic arthritis (PsA) who were new users of targeted therapies, France, 1 January 2015 to 30 June 2021 (mean age 48.7±12.7 years; 57.7% women)
- Participants
- 12,071 adults
- Exposure
- Targeted therapies vs adalimumab
- Outcome
- Serious infection (ie, requiring hospitalisation), time-to-event
Methodological detailspropensity score-weighted Cox models, inverse propensity score weighting, adjustment for time-dependent covariates and calendar year, French health insurance database linked to hospital discharge database
- Propensity score-weighted Cox models
- Inverse propensity score weighting
- Adjustment for time-dependent covariates and calendar year
- French health insurance database linked to hospital discharge database
Main finding
As reported in the abstract
Serious infection
Each group vs adalimumabWeighted hazard ratio (95% CI)
Etanercept
0.72(0.53–0.97)
Ustekinumab
0.57(0.35–0.93)
- Serious infections, all patients
- 367 (3.0% of patients)
- Crude incidence rate per 1000 person-years
- 17.0 (95% CI, 15.2 to 18.7)
Observational data: associations, not effects.
Original publication
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS). RMD Open. Published 14 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →